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Staphylococcus aureus in the nose is a risk factor for endogenous staphylococcal infection. UK guide-
lines recommend the use of mupirocin for nasal decolonization in certain groups of patients colonized
with methicillin-resistant S. aureus (MRSA). Mupirocin is effective at removing S. aureus from the nose
over a few weeks, but relapses are common within several months. There are only a few prospective
randomized clinical trials that have been completed with sufficient patients, but those that have been
reported suggest that clearance of S. aureus from the nose is beneficial in some patient groups for the
reduction in the incidence of nosocomial infections. There is no convincing evidence that mupirocin
treatment reduces the incidence of surgical site infection. New antibiotics are needed to decolonize
the nose because bacterial resistance to mupirocin is rising, and so it will become less effective.
Furthermore, a more bactericidal antibiotic than mupirocin is needed, on the grounds that it might
reduce the relapse rate, and so clear the patient of MRSA for a longer period of time than mupirocin.
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Nasal decolonization of methicillin-susceptible Staphylococcus
aureus (MSSA) and methicillin-resistant S. aureus (MRSA) is
currently used in some countries for specific patient groups. For
example, in the UK it is recommended1 that carriers of MRSA,
who are receiving prophylaxis for an operation, should undergo
nasal decolonization with mupirocin. Mupirocin is effective at
removing S. aureus from the nose over a few weeks, but nasal
relapses are common within several months.2 There are few pro-
spective randomized clinical trials (RCTs) with sufficient
patients to achieve statistical significance that have been com-
pleted in this field.3 Taken together, these trials suggest that
clearance of S. aureus from the nose is beneficial in some
patient groups.4 This paper describes the risks, benefits and
importance of patient selection in the use of mupirocin to deco-
lonize the anterior nares.
S. aureus strains
MSSA lives on the skin of humans as a commensal. In devel-
oped countries 30%5–7 of the general adult population are
colonized, although the data range from as low as 15%8 up to
100%, in specific populations, such as those with MSSA skin
infections.9 Nasal colonization (stable colonization is defined as
S. aureus in the nose detected from nasal swabs taken several
days apart) with strains such as MRSA is much lower, at 1%
of the total population,10 and is more frequent in certain sub-
groups of patients such as frequently hospitalized people, those
of advancing age, patients on dialysis, AIDS patients and
diabetics.1,11
Colonization with MRSA has been shown to increase the
risk of infection with MRSA both immediately after coloni-
zation12 and in long-term carriers, of whom 23% develop
MRSA infections in the year following the identification of
their carriage status.13 Patients who have had contact with
healthcare facilities such as hospitals may be colonized in
the nose with healthcare-associated (HA) MRSA. A different
set of MRSA strains affects patients who have not had
recent contact with healthcare units, and these strains are
called community-associated (CA) MRSA. HA-MRSA
usually causes diseases such as bacteraemia and infective
endocarditis that tend to be more multiresistant. In contrast
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CA-MRSA tends to affect younger, healthy people, causing
skin and soft tissue infections and other infections such as
the serious necrotizing pneumonia.11 It is currently less mul-
tiresistant than HA-MRSA and is usually susceptible to com-
monly used antibiotics such as tetracyclines, but is more
virulent, e.g. it invades tissue more readily, partly as a result
of some strains that carry the Panton-Valentine leucocidin
toxin gene.14
Methicillin resistance of MRSA is determined by carriage of
the mecA gene that encodes a variant of the penicillin binding
protein 2A, which has a low affinity for b-lactam antibiotics.
The mecA gene is found on the staphylococcal cassette chromo-
some (SCC). Different strains of MRSA have SSCmec numbered
I to VI. SCCmec types I to III are typically found in
HA-MRSA,15 while CA-MRSA characteristically carries the two
smallest SCCmec, types IV16 and V.17 CA-MRSA grows faster
in vitro than HA-MRSA, indicating a greater genetic fitness in
the absence of the selection pressures from the widespread use
of antimicrobials that shaped the genetic background of
HA-MRSA strains.14 CA-MRSA is thought to be currently using
some of the more ‘successful’ genetic lineages from MSSA such
as ST30 (Oceania clone) or ST8 (USA 300 clone).15 Around the
world CA-MRSA is presenting with changing resistance pro-
files14 and outbreaks outside hospitals have been reported from
close communities such as prisons,18 military barracks,19 rafting
guide companies20 and American football teams.21 This evol-
ution towards communicability and toxicity is likely to present
new challenges for infection control.
Morbidity, mortality and economic impact of
S. aureus disease
It has been estimated22 that S. aureus in the USA in 2005 was
responsible for 478000 nosocomial infections, 58% from
MRSA, that progressed to cause 10800 deaths overall with 5500
from MRSA. Although MRSA has been associated with higher
infection23 rates than MSSA, it is thought that at least some of
this effect is due to differences in the severity of co-morbid
illness.24 The cost to health services of controlling and treating
S. aureus infections is high with one study in the USA
suggesting $9.7 billion in 2001.25 The impact of S. aureus
infections on society as a whole is harder to quantify.
S. aureus transmission and adhesion
The ways in which S. aureus is transmitted and the mechanisms
behind its survival in the nasal environment are important factors
in colonization. It is likely that transmission from one individual
to another is mediated by hand-to-nose contact, indicated by the
association of hand carriage,26 and of habitual nose-picking,27 to
nasal carriage. Aerial transmission28 is an alternative route and
may be particularly important in instances of colonized patients
with allergies who tend to release higher S. aureus loads.29,30
Having reached the anterior nares, the next step towards success-
ful colonization is for the bacteria to effectively adhere to the
nasal epithelial cells. Interactions between humans and S. aureus
determine the nature of the nasal carriage and are influenced by
the genotypes of both the host and microbe.31
Competition between staphylococci for colonization
in the anterior nares
The ‘ecological niche’ of the anterior nares has a finite area that
can be colonized and there is competition between different gen-
otypes for this space. One study32 observed nasal colonization
with MSSA in 17% of patients and 8% with MRSA.
However, only 0.6% were co-colonized with both and so the
investigators concluded that, whilst different organisms can
compete for the same niche, in this case MSSA has greater
fitness, which suggests that it may prevent colonization by
MRSA. The fitness advantage of MSSA over MRSA can be
accounted for by the added resistance mechanism(s) of MRSA
that incur viability and competitiveness costs.33,34
Does nasal colonization with S. aureus matter?
Nasal colonization as a risk factor for S. aureus disease
S. aureus (including MRSA) colonization of the nose is an
endemic risk factor for infectious diseases such as bacteraemia
and skin and soft tissue infections in many patient populations,6
e.g. the general hospital population,35 patients undergoing
general,5 thoracic36 and orthopaedic37 surgery, patients being
treated in intensive care units (ICUs),38 non-surgical patients
(including those on haemodialysis),39 continuous ambulatory
peritoneal dialysis (CAPD) patients,40 HIV-positive patients41
and liver transplant patients.42
It seems that most S. aureus disease is caused by the patient’s
own bacteria. The rates of S. aureus autoinfection, where the
S. aureus strain detected from the wound matches that swabbed
from the nose, are high both in observational studies and in
RCTs. Autoinfection rates tend to lie between 76% and
86%.3,43–45 The density at which the anterior nares are colo-
nized may be a further risk factor; a 3-fold increase in surgical
site infections (SSIs) has been reported in surgical patients with
high concentrations of nasal S. aureus.37 These associations do
not necessitate causality and both could conceivably be pro-
duced by a third party such as immunological changes influen-
cing bacterial activity. Crucially though, evidence that nasal
S. aureus decolonization leads to a decreased incidence of
S. aureus infection in certain cases, is an important indication
that nasal colonization is implicated in autoinfection.3,4
Mupirocin removes MRSA and MSSA from the nose
Mupirocin is established as the best topical antimicrobial avail-
able for Gram-positive bacteria1,46 and has been applied to the
task of nasal decolonization since the 1980s to target nasal
S. aureus carriage on the grounds that S. aureus carriage is a
risk factor for S. aureus disease.47 It is a relatively potent deco-
lonizing agent; immediately after completion of nasal mupirocin
treatment, 81.5% to 100% of patients are successfully decolo-
nized compared with spontaneous or vehicle-mediated decoloni-
zation rates of 0% to 46%.3,48–50 Under everyday working
conditions, poor patient compliance may reduce the effect
further. For example, in one case, mupirocin only decolonized
6% of patients.50
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Mupirocin resistance
Mupirocin acts on isoleucyl tRNA synthetase to inhibit protein
synthesis.51 It is this enzyme that is the focal point of resistance.
Emergence of bacterial resistance to mupirocin, in many cases,
is rising.52,53 Interestingly though, significant increases in resist-
ance to mupirocin have been reported in one hospital with only
light mupirocin usage,54 while regular usage in another was not
sufficient to increase the mupirocin resistance.55 There are two
phenotypes of mupirocin-resistant S. aureus, ‘low-level’ and
‘high-level’ (LL-MR and HL-MR, respectively), and both are
able to cause treatment failure.56 The working definition of
LL-MR is a mupirocin MIC of 8–256 mg/L and the working
definition of HL-MR is a mupirocin MIC of 512 mg/L. The
LL-MR genotype is a mutation of the chromosomal gene ileS-2
(mupA), which encodes a resistant version of isoleucyl tRNA
synthetase, while HL-MR’s genotype is a plasmid-transferrable
alternative version of the same gene.34 An estimated 6.6% of
patients who carry S. aureus are colonized with multiple
strains,57 so presenting an opportunity for horizontal gene trans-
fer both for developing new strains58 and perpetuating the resist-
ance genes themselves. The plasmid can be incorporated into
other species such as Staphylococcus epidermidis59 to act as a
potential reservoir.60 The mutation behind LL-MR is readily
induced by exposure to mupirocin in vitro.61 This resilience of
S. aureus resistance mechanisms means that mupirocin resist-
ance is unlikely to be eradicated on the removal, or restriction,
of mupirocin use, particularly as LL-MR mutations are not
associated with a significant fitness burden over mupirocin-
susceptible S. aureus.34
In one study56 decolonization was achieved on day 3 after
mupirocin treatment in 78.5% of mupirocin-susceptible MRSA,
80% of LL-MR MRSA and 27.7% of HL-MR MRSA. At
4 weeks, 91% of the mupirocin-susceptible MRSA group were
still culture-negative, whilst only 25% of both the LL-MR and
HL-MR MRSA groups were culture-negative. This 75% LL-MR
MRSA persistence suggests even low-level resistance is suffi-
cient to lead to treatment failure. If mupirocin-susceptible
MRSA and LL-MR MRSA can be considered to have similar
exogenous infection rates, then this result indicates that LL-MR
MRSA recolonization is due to endogenous relapse rather than
exogenous recolonization. The endogenous relapse may be
attributable to latent bacterial sub-populations that may be diffi-
cult to detect by culture methods.62
Does nasal decolonization benefit the patient?
There are only a few3,45,48 prospective RCTs that have been
completed with sufficient patients, assessing the benefits of
nasal decolonization, but those that have been reported suggest
that the clearance of S. aureus from the nose is beneficial in
some patient groups.
Surgery
In clean elective surgery in developed countries, the baseline
rate for SSI is 1%–5% of which S. aureus causes 30%–50%.63
A recent study,48 with strong methodology and the only prospec-
tive RCT assessing SSIs performed with blinding during the
data analysis, found that, despite clearing 81.5% of nasal
S. aureus, no significant effect of mupirocin on the outcome of
SSIs caused by S. aureus occurred (total S. aureus infections:
3.8% mupirocin, 3.2% placebo; P¼1.00, CI¼ 0.32–4.69).
Another large RCT, by Perl et al.,3 concluded that mupirocin
did not significantly reduce S. aureus SSIs, but that it did signifi-
cantly reduce the total number of nosocomial S. aureus infec-
tions among the S. aureus carriers. A third study45 found that
mupirocin did not significantly reduce the S. aureus SSI rate
even though there were 5-fold fewer endogenous S. aureus SSIs
in the mupirocin group than in the control group.
One shared issue48 that runs through these trials is that
mupirocin has a minimal effect in reducing infections in uncolo-
nized individuals. This dilutes the power of these studies and
could contribute to the non-significant results found by both Perl
et al.3 and Kalmeijer et al.,45 but not for those found in the later
2006 study48 (which used data only from colonized patients).
Another factor that may have led to the lower than average
infection rates in these trials, hence further power dilution, is
simply that participation in studies induces healthcare staff to
maintain higher standards of hygiene and care, similar to the
effect observed by French et al.64 in 1989, and may have led the
investigators in the smaller trials to underestimate the number of
subjects needed to contract disease.48 Nonetheless, the results
from the two 2002 trials can be combined to increase the power
of the trends that were shown to near statistical significance
(P¼0.06, pooled OR¼0.58, 95% CI¼0.33–1.02). A recent
meta-analysis4 suggested that these three trials, together with
one other,65 gave pooled results that, although still failing to
substantiate nasal S. aureus decolonization with mupirocin as a
means of reducing S. aureus SSIs, did generate sufficient signifi-
cance to support mupirocin as an effective means to reduce all
postoperative S. aureus infections, including SSI. In this study,4
3.6% of S. aureus infectious diseases occurred in the mupirocin-
treated group versus 6.7% in the controls (RR¼0.55, 95%
CI¼0.34–0.89, P¼0.02).
Very large numbers of patients would be needed to confirm
intranasal mupirocin’s efficacy in reducing SSI with statistical
significance. It is estimated that 14000 patients66 with a base-
line SSI rate of 5% would be needed to demonstrate a 20%
reduction in the SSI rate. It is not likely that this study will be
undertaken, because of the large investment that would be
required in relation to the size of the market.
ICUs
MRSA constitutes .64% of S. aureus isolates in US ICUs.67
One study reported that 8% of admissions to ICUs carried
MRSA in the nose and the acquisition of MRSA carriage
whilst in the ICU was 10%.68 The high prevalence of MRSA
in ICUs presents a threat to the rest of the hospital population
when patients are discharged from the ICU into other hospital
wards with their accompanying MRSA69 and, therefore, nasal
decolonization with mupirocin may be useful in ICUs. In a
prospective, randomized double-blinded study70 it was
suggested that the inclusion of mupirocin, intranasally and in
an oral paste, significantly reduced MRSA lung infections (7
of 104 cases in the placebo group versus 1 of 119 cases in
the treatment group; P,0.05). Further clinical trials suggest
that mupirocin is useful for reducing endogenous MRSA
infections in ICUs.71
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Long-term mupirocin treatment
Studies looking at the long-term efficacy of mupirocin that have
focused on nasal decolonization of S. aureus, including MRSA,
have shown that initial clearance over several weeks is effective
but that recolonization after 3 months is high.2,72 It has been
established that significant increases in resistance to mupirocin
can occur after repeated or extended courses of mupirocin73 and,
in order to maximize the potential therapeutic benefits of mupir-
ocin, it is recommended this such usage is avoided.1 In dialysis
patients, mupirocin treatment regimens have been described as
effectively reducing infection although also increasing the preva-
lence of resistance to mupirocin.74 However, it is possible to
simply reduce the prevalence of S. aureus colonization without
altogether eliminating carriage so minimizing the potential for
induction of resistance. In care homes, 3 months after effective
decolonization, recolonization rates are 39%75 to 24%.76 Of
these recolonizations, 86% were relapses rather than exogenous
recolonization.75 Another study, in a gastroenterology unit, indi-
cated that mupirocin significantly reduced nasal MRSA coloni-
zation and infection rates over 55 months using a single course
of mupirocin.77 In a study on healthy hospital staff, intranasal
mupirocin affected a near complete decolonization; 6 months
after treatment nasal colonization was 56% (the placebo group
maintained 72% colonization) while 1 year after treatment nasal
carriage was 53% (the placebo group maintained 76% coloniza-
tion; RR¼0.70, 95% CI¼0.48–1.02, P¼0.056).2
What are the alternatives?
New antibiotics are needed to decolonize the nose due to the
rise in bacterial resistance to mupirocin and its subsequent
reduction in effectiveness. Additionally, a more bactericidal anti-
biotic than mupirocin is needed on the grounds that it might
reduce the relapse rate, so clearing the patient of S. aureus for a
longer period of time than mupirocin and reducing the associ-
ated risks of infection. We have not included other agents that
are currently used in some countries, such as neomycin, chlor-
hexidene or fusidic acid, because, in a limited number of clinical
trials, these agents have been shown to be either less effective
than mupirocin or are not licensed for nasal decolonization of
staphylococci.78,79
Drugs coming on to the market
A number of drugs, at varying stages of development, which
might be more effective for nasal S. aureus decolonization than
mupirocin, are on their way to the market. These come from a
range of sources, large as well as small pharmaceutical compa-
nies (in the case of Replidyne, with inputs from both). The
drugs have a diversity of mechanisms.
Replidyne’s REP8839 has a similar mechanism of action to
mupirocin, acting on the methionyl tRNA synthetase (MetRS)
rather than isoleucyl tRNA synthetase to inhibit protein syn-
thesis. MetRS is thought to be a particularly good target as it
takes the first step in translating the methionine required for both
the initiation and elongation of peptide chains in vitro. REP8839
is active against Gram-positive skin bacteria such as S. aureus
and Streptococcus pyogenes. The drug completed Phase I clini-
cal trials in 2007,80 but its development has since slowed.
Novabay’s N,N-dichloro-2,2-dimethyltaurine is a stabilized ana-
logue of the endogenous N-chlorotaurine oxidants synthesized
by activated granulocytes.81 Also known as NVC-422, the
oxidant finished, in May 2008, Phase IIa clinical trials as a deco-
lonization spray for nasal S. aureus, clearing 88% of colonized
subjects.82 Destiny Pharma is adapting the principles of photo-
dynamic therapy to antimicrobials with its lead compound
XF-73. XF-73 is a photosensitive porphyrin derivative that
causes a light-dependent disruption of membrane integrity83 and
has shown potent clearance of MRSA on ex vivo porcine skin
samples.84
Phico Therapeutics85 is developing a bacteriophage approach
to eliminate S. aureus and, in particular, MRSA. Its lead pro-
gramme, SASPjectTM, has completed pre-clinical trials for nasal
decolonization. Its in vitro activity against different S. aureus
strains, bar vancomycin-intermediate S. aureus/vancomycin-
resistant S. aureus, is .3 log reduction in viable counts after
6 h. The modified S. aureus-specific bacteriophage PTSA1.2/A
delivers the complementary a/b-type small acid-soluble spore
protein gene from Bacillus megaterium, which is then translated
into its protein that flips the bacterial DNA A-B resulting in bac-
terial cell death. The SASPjectTM application is focused and
confined by the removal of the holin gene from the phage to
prevent budding and so viral propagation.
Helperby Therapeutics86 has developed the compound HT61,
which showed a bactericidal effect against MSSA and MRSA in
the nose in a Phase IIa clinical trial. HT61 is active against
persistent bacteria that are not killed by antibiotics such as
mupirocin.
NICE report
The UK’s National Institute of Clinical Excellence (NICE) pub-
lished a report87 on 22 October 2008 on SSIs, which states:
‘There is evidence that nasal decontamination with mupirocin or
chlorhexidine administered to all patients undergoing surgery
does not affect the overall rate of SSI. There is evidence that
nasal decontamination with mupirocin given to S. aureus car-
riers undergoing surgery does not reduce either the incidence of
S. aureus SSI or the incidence of all-cause SSI.’
NICE does not recommend the routine use of topical antimi-
crobial agents for nasal decontamination aimed at eliminating
S. aureus to reduce the risk of SSIs.
We agree with the recommendations of the NICE report, but
emphasize that there is evidence that mupirocin treatment
reduces the incidence of S. aureus nosocomial infections in
S. aureus carriers. The report does not comment on the use of
mupirocin for the prevention of nosocomial infections.
Accordingly, we suggest that usage of mupirocin should concen-
trate on the prevention of nosocomial infections in carriers. The
reason for the failure of mupirocin to prevent SSIs is unknown,
but may be due to lack of power in the clinical trials55 or to a
lack of efficacy of mupirocin in this patient sub-group.
Conclusions
The evidence suggests that intranasal mupirocin is a useful tool
for reducing S. aureus autoinfection when patients are at high-
risk in the short-term, such as in an ICU. Whilst it reduces the
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risk of nosocomial infection, it has not been shown to reduce the
risk of SSIs. It is also useful for reducing symptomless spread in
hospitals. When patients are at risk of colonization and infection
from MRSA, such as those patients on long-term haemodialysis,
CAPD and in care homes, its utility is limited by the need to
avoid the induction of resistance to it. The rising emergence of
S. aureus resistance to mupirocin will eventually reach a point at
which its benefits are restricted to the extent that its use is no
longer economically viable. It is vital that at least some of
the new antimicrobial therapies under development reach the
market, both to provide a more effective solution to the issue of
long-term nasal colonization and to replace mupirocin when it
becomes redundant.
Acknowledgements
We thank Mark Farrington for his helpful comments on the
manuscript.
Transparency declarations
A. C. and R. B. are directors and shareholders of Helperby
Therapeutics Group plc. A. C. receives grants from Helperby
Therapeutics and a grant from the Burton Trust.
Helperby Therapeutics is currently developing an antimicrobial
in this field. T. C. none to declare.
References
1. Coia JE, Duckworth GJ, Edwards DI et al. Guidelines for the
control and prevention of methicillin-resistant Staphylococcus aureus
(MRSA) in healthcare facilities. J Hosp Infect 2006; 63 Suppl 1:
S1–44.
2. Doebbeling BN, Reagan DR, Pfaller MA et al. Long-term efficacy
of intranasal mupirocin ointment. A prospective cohort study of
Staphylococcus aureus carriage. Arch Intern Med 1994; 154: 1505–8.
3. Perl TM, Cullen JJ, Wenzel RP et al. Intranasal mupirocin to
prevent postoperative Staphylococcus aureus infections. N Engl J Med
2002; 346: 1871–7.
4. van Rijen MM, Bonten M, Wenzel RP et al. Intranasal mupirocin
for reduction of Staphylococcus aureus infections in surgical patients
with nasal carriage: a systematic review. J Antimicrob Chemother
2008; 61: 254–61.
5. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of
Staphylococcus aureus: epidemiology, underlying mechanisms, and
associated risks. Clin Microbiol Rev 1997; 10: 505–20.
6. Wertheim HF, Melles DC, Vos MC et al. The role of nasal car-
riage in Staphylococcus aureus infections. Lancet Infect Dis 2005; 5:
751–62.
7. Gorwitz RJ, Kruszon-Moran D, McAllister SK et al. Changes in
the prevalence of nasal colonization with Staphylococcus aureus in the
United States, 2001–2004. J Infect Dis 2008; 197: 1226–34.
8. Anwar MS, Jaffery G, Rehman Bhatti KU et al. Staphylococcus
aureus and MRSA nasal carriage in general population. J Coll
Physicians Surg Pak 2004; 14: 661–4.
9. Nahmias AJ, Lepper MH, Hurst V et al. Epidemiology and treat-
ment of chronic staphylococcal infections in the household. Am J
Public Health Nations Health 1962; 52: 1828–43.
10. Tenover FC, McAllister S, Fosheim G et al. Characterization of
Staphylococcus aureus isolates from nasal cultures collected from indi-
viduals in the United States in 2001 to 2004. J Clin Microbiol 2008; 46:
2837–41.
11. Boucher HW, Corey GR. Epidemiology of methicillin-resistant
Staphylococcus aureus. Clin Infect Dis 2008; 46 Suppl 5: S344–9.
12. Coello R, Glynn JR, Gaspar C et al. Risk factors for developing
clinical infection with methicillin-resistant Staphylococcus aureus
(MRSA) amongst hospital patients initially only colonized with MRSA.
J Hosp Infect 1997; 37: 39–46.
13. Datta R, Huang SS. Risk of infection and death due to
methicillin-resistant Staphylococcus aureus in long-term carriers. Clin
Infect Dis 2008; 47: 176–81.
14. Tristan A, Ferry T, Durand G et al. Virulence determinants in
community and hospital methicillin-resistant Staphylococcus aureus.
J Hosp Infect 2007; 65 Suppl 2: 105–9.
15. de Lencastre H, Oliveira D, Tomasz A. Antibiotic resistant
Staphylococcus aureus: a paradigm of adaptive power. Curr Opin
Microbiol 2007; 10: 428–35.
16. Daum RS, Ito T, Hiramatsu K et al. A novel methicillin-resistance
cassette in community-acquired methicillin-resistant Staphylococcus
aureus isolates of diverse genetic backgrounds. J Infect Dis 2002; 186:
1344–7.
17. Ito T, Ma XX, Takeuchi F et al. Novel type V staphylococcal cas-
sette chromosome mec driven by a novel cassette chromosome
recombinase, ccrC. Antimicrob Agents Chemother 2004; 48: 2637–51.
18. David MZ, Mennella C, Mansour M et al. Predominance of
methicillin-resistant Staphylococcus aureus among pathogens causing
skin and soft tissue infections in a large urban jail: risk factors and
recurrence rates. J Clin Microbiol 2008; 46: 3222–7.
19. Campbell KM, Vaughn AF, Russell KL et al. Risk factors for
community-associated methicillin-resistant Staphylococcus aureus
infections in an outbreak of disease among military trainees in
San Diego, California, in 2002. J Clin Microbiol 2004; 42: 4050–3.
20. Decker MD, Lybarger JA, Vaughn WK et al. An outbreak of sta-
phylococcal skin infections among river rafting guides. Am J Epidemiol
1986; 124: 969–76.
21. Bowers AL, Huffman GR, Sennett BJ. Methicillin-resistant
Staphylococcus aureus infections in collegiate football players. Med
Sci Sports Exerc 2008; 40: 1362–7.
22. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths
caused by methicillin-resistant Staphylococcus aureus, United States,
1999–2005. Emerg Infect Dis 2007; 13: 1840–6.
23. Safdar N, Bradley EA. The risk of infection after nasal
colonization with Staphylococcus aureus. Am J Med 2008; 121:
310–5.
24. Shurland S, Zhan M, Bradham DD et al. Comparison of mortality
risk associated with bacteraemia due to methicillin-resistant and
methicillin-susceptible Staphylococcus aureus. Infect Control Hosp
Epidemiol 2007; 28: 273–9.
25. Noskin GA, Rubin RJ, Schentag JJ et al. The burden of
Staphylococcus aureus infections on hospitals in the United States: an
analysis of the 2000 and 2001 Nationwide Inpatient Sample Database.
Arch Intern Med 2005; 165: 1756–61.
26. Doebbeling BN. Nasal and hand carriage of Staphylococcus
aureus in healthcare workers. J Chemother 1994; 6 Suppl 2: 11–7.
27. Wertheim HF, van Kleef M, Vos MC et al. Nose picking and
nasal carriage of Staphylococcus aureus. Infect Control Hosp
Epidemiol 2006; 27: 863–7.
28. Wilson RD, Huang SJ, McLean AS. The correlation between air-
borne methicillin-resistant Staphylococcus aureus with the presence of
MRSA colonized patients in a general intensive care unit. Anaesth
Intensive Care 2004; 32: 202–9.
Review
13
29. Bischoff WE, Wallis ML, Tucker BK et al. “Gesundheit!” sneez-
ing, common colds, allergies, and Staphylococcus aureus dispersion.
J Infect Dis 2006; 194: 1119–26.
30. Bischoff WE, Tucker BK, Wallis ML et al. Preventing the air-
borne spread of Staphylococcus aureus by persons with the common
cold: effect of surgical scrubs, gowns, and masks. Infect Control Hosp
Epidemiol 2007; 28: 1148–54.
31. Emonts M, Uitterlinden AG, Nouwen JL et al. Host polymorph-
isms in interleukin 4, complement factor H, and C-reactive protein
associated with nasal carriage of Staphylococcus aureus and
occurrence of boils. J Infect Dis 2008; 197: 1244–53.
32. Dall’Antonia M, Coen PG, Wilks M et al. Competition between
methicillin-sensitive and -resistant Staphylococcus aureus in the
anterior nares. J Hosp Infect 2005; 61: 62–7.
33. Andersson DI, Levin BR. The biological cost of antibiotic resist-
ance. Curr Opin Microbiol 1999; 2: 489–93.
34. Hurdle JG, O’Neill AJ, Ingham E et al. Analysis of mupirocin
resistance and fitness in Staphylococcus aureus by molecular genetic
and structural modeling techniques. Antimicrob Agents Chemother
2004; 48: 4366–76.
35. Davis KA, Stewart JJ, Crouch HK et al. Methicillin-resistant
Staphylococcus aureus (MRSA) nares colonization at hospital admis-
sion and its effect on subsequent MRSA infection. Clin Infect Dis 2004;
39: 776–82.
36. Munoz P, Hortal J, Giannella M et al. Nasal carriage of
S. aureus increases the risk of surgical site infection after major heart
surgery. J Hosp Infect 2008; 68: 25–31.
37. Kalmeijer MD, van Nieuwland-Bollen E, Bogaers-Hofman D
et al. Nasal carriage of Staphylococcus aureus is a major risk factor for
surgical-site infections in orthopaedic surgery. Infect Control Hosp
Epidemiol 2000; 21: 319–23.
38. Garrouste-Orgeas M, Timsit JF, Kallel H et al. Colonization with
methicillin-resistant Staphylococcus aureus in ICU patients: morbidity,
mortality, and glycopeptide use. Infect Control Hosp Epidemiol 2001;
22: 687–92.
39. Yu VL, Goetz A, Wagener M et al. Staphylococcus aureus nasal
carriage and infection in patients on haemodialysis. Efficacy of anti-
biotic prophylaxis. N Engl J Med 1986; 315: 91–6.
40. Nouwen J, Schouten J, Schneebergen P et al. Staphylococcus
aureus carriage patterns and the risk of infections associated with con-
tinuous peritoneal dialysis. J Clin Microbiol 2006; 44: 2233–6.
41. Nguyen MH, Kauffman CA, Goodman RP et al. Nasal carriage
of and infection with Staphylococcus aureus in HIV-infected patients.
Ann Intern Med 1999; 130: 221–5.
42. Chang FY, Singh N, Gayowski T et al. Staphylococcus aureus
nasal colonization and association with infections in liver transplant
recipients. Transplantation 1998; 65: 1169–72.
43. von Eiff C, Becker K, Machka K et al. Nasal carriage as a
source of Staphylococcus aureus bacteraemia. N Engl J Med 2001;
344: 11–6.
44. Wertheim HF, Vos MC, Ott A et al. Risk and outcome of
nosocomial Staphylococcus aureus bacteraemia in nasal carriers
versus non-carriers. Lancet 2004; 364: 703–5.
45. Kalmeijer MD, Coertjens H, van Nieuwland-Bollen PM et al.
Surgical site infections in orthopaedic surgery: the effect of mupirocin
nasal ointment in a double-blind, randomized, placebo-controlled
study. Clin Infect Dis 2002; 35: 353–8.
46. Gould JC, Smith JH, Moncur H. Mupirocin in General Practice: a
placebo controlled trial. In: Wilkinson DS, Price JD, eds. International
Congress and Symposium Series. Number 80. Mupirocin, A Novel
Topical Antibiotic. London: Royal Society of Medicine, 1984; 85–93.
47. Casewell MW, Hill RLR, Duckworth GJ. The effect of mupirocin
(pseudomonic acid) on the nasal carriage of Staphylococcus aureus.
In: Dobson RL, Leyden JJ, Noble WC et al., eds. Excerpta Medica–
Current Clinical Practice Series No. 16. Bactroban (mupirocin).
Proceedings of an International Symposium. Amsterdam: Elsevier,
1985; 47–53.
48. Konvalinka A, Errett L, Fong IW. Impact of treating
Staphylococcus aureus nasal carriers on wound infections in cardiac
surgery. J Hosp Infect 2006; 64: 162–8.
49. Doebbeling BN, Breneman DL, Neu HC et al. Elimination of
Staphylococcus aureus nasal carriage in health care workers: analysis
of six clinical trials with calcium mupirocin ointment. The Mupirocin
Collaborative Study Group. Clin Infect Dis 1993; 17: 466–74.
50. Hansen D, Patzke PI, Werfel U et al. Success of MRSA eradica-
tion in hospital routine: depends on compliance. Infection 2007; 35:
260–4.
51. Hughes J, Mellows G. On the mode of action of pseudomonic
acid: inhibition of protein synthesis in Staphylococcus aureus.
J Antibiot (Tokyo) 1978; 31: 330–5.
52. Simor AE, Stuart TL, Louie L et al. Mupirocin-resistant,
methicillin-resistant Staphylococcus aureus strains in Canadian hospi-
tals. Antimicrob Agents Chemother 2007; 51: 3880–6.
53. Fujimura S, Watanabe A. Survey of high- and low-level
mupirocin-resistant strains of methicillin-resistant Staphylococcus
aureus in 15 Japanese hospitals. Chemotherapy 2003; 49: 36–8.
54. Jones JC, Rogers TJ, Brookmeyer P et al. Mupirocin resistance
in patients colonized with methicillin-resistant Staphylococcus aureus in
a surgical intensive care unit. Clin Infect Dis 2007; 45: 541–7.
55. Fawley WN, Parnell P, Hall J et al. Surveillance for mupirocin
resistance following introduction of routine peri-operative prophylaxis
with nasal mupirocin. J Hosp Infect 2006; 62: 327–32.
56. Walker ES, Vasquez JE, Dula R et al. Mupirocin-resistant,
methicillin-resistant Staphylococcus aureus: does mupirocin remain
effective? Infect Control Hosp Epidemiol 2003; 24: 342–6.
57. Cespedes C, Said-Salim B, Miller M et al. The clonality of
Staphylococcus aureus nasal carriage. J Infect Dis 2005; 191:
444–52.
58. Diep BA, Carleton HA, Chang RF et al. Roles of 34 virulence
genes in the evolution of hospital- and community-associated strains of
methicillin-resistant Staphylococcus aureus. J Infect Dis 2006; 193:
1495–503.
59. Janssen DA, Zarins LT, Schaberg DR et al. Detection and
characterization of mupirocin resistance in Staphylococcus aureus.
Antimicrob Agents Chemother 1993; 37: 2003–6.
60. Bastos MC, Mondino PJ, Azevedo ML et al. Molecular charac-
terization and transfer among Staphylococcus strains of a plasmid con-
ferring high-level resistance to mupirocin. Eur J Clin Microbiol Infect
Dis 1999; 18: 393–8.
61. Casewell MW, Hill RL. In vitro activity of mupirocin (‘pseudo-
monic acid’) against clinical isolates of Staphylococcus aureus.
J Antimicrob Chemother 1985; 15: 523–31.
62. Coates A, Hu Y, Bax R et al. The future challenges facing the
development of new antimicrobial drugs. Nat Rev Drug Discov 2002; 1:
895–910.
63. Trautmann M, Stecher J, Hemmer W et al. Intranasal mupirocin
prophylaxis in elective surgery. A review of published studies.
Chemotherapy 2008; 54: 9–16.
64. French GL, Cheng AF, Wong SL et al. Repeated prevalence
surveys for monitoring effectiveness of hospital infection control.
Lancet 1989; ii: 1021–3.
65. Garcia AM, Villa MV, Escudero ME et al. [Use of nasal mupiro-
cin for Staphylococcus aureus: effect on nasal carriers and nosocomial
infections]. Biomedica 2003; 23: 173–9.
66. Kallen AJ, Wilson CT, Larson RJ. Perioperative intranasal mupir-
ocin for the prevention of surgical-site infections: systematic review of
the literature and meta-analysis. Infect Control Hosp Epidemiol 2005;
26: 916–22.
Review
14
67. Klevens RM, Edwards JR, Tenover FC et al. Changes in the epi-
demiology of methicillin-resistant Staphylococcus aureus in intensive
care units in US hospitals, 1992–2003. Clin Infect Dis 2006; 42:
389–91.
68. Warren DK, Guth RM, Coopersmith CM et al. Epidemiology
of methicillin-resistant Staphylococcus aureus colonization in a
surgical intensive care unit. Infect Control Hosp Epidemiol 2006; 27:
1032–40.
69. Gould IM, MacKenzie FM, MacLennan G et al. Topical
antimicrobials in combination with admission screening and barrier
precautions to control endemic methicillin-resistant Staphylococcus
aureus in an intensive care unit. Int J Antimicrob Agents 2007; 29:
536–43.
70. Nardi G, Di Silvestre AD, De Monte A et al. Reduction in gram-
positive pneumonia and antibiotic consumption following the use of
a SDD protocol including nasal and oral mupirocin. Eur J Emerg Med
2001; 8: 203–14.
71. Muller A, Talon D, Potier A et al. Use of intranasal mupirocin to
prevent methicillin-resistant Staphylococcus aureus infection in inten-
sive care units. Crit Care 2005; 9: R246–50.
72. Fernandez C, Gaspar C, Torrellas A et al. A double-blind,
randomized, placebo-controlled clinical trial to evaluate the safety and
efficacy of mupirocin calcium ointment for eliminating nasal carriage of
Staphylococcus aureus among hospital personnel. J Antimicrob
Chemother 1995; 35: 399–408.
73. Vasquez JE, Walker ES, Franzus BW et al. The epidemiology of
mupirocin resistance among methicillin-resistant Staphylococcus
aureus at a Veterans’ Affairs hospital. Infect Control Hosp Epidemiol
2000; 21: 459–64.
74. Tacconelli E, Carmeli Y, Aizer A et al. Mupirocin prophylaxis to
prevent Staphylococcus aureus infection in patients undergoing dialy-
sis: a meta-analysis. Clin Infect Dis 2003; 37: 1629–38.
75. Mody L, Kauffman CA, McNeil SA et al. Mupirocin-based deco-
lonization of Staphylococcus aureus carriers in residents of 2 long-term
care facilities: a randomized, double-blind, placebo-controlled trial. Clin
Infect Dis 2003; 37: 1467–74.
76. Watanakunakorn C, Axelson C, Bota B et al. Mupirocin ointment
with and without chlorhexidine baths in the eradication of
Staphylococcus aureus nasal carriage in nursing home residents. Am
J Infect Control 1995; 23: 306–9.
77. Dupeyron C, Campillo B, Richardet JP et al. Long-term efficacy
of mupirocin in the prevention of infections with meticillin-resistant
Staphylococcus aureus in a gastroenterology unit. J Hosp Infect 2006;
63: 385–92.
78. Leigh DA, Joy G. Treatment of familial staphylococcal infection–
comparison of mupirocin nasal ointment and chlorhexidine/neomycin
(Naseptin) cream in eradication of nasal carriage. J Antimicrob
Chemother 1993; 31: 909–17.
79. Parras F, Guerrero MC, Bouza E et al. Comparative study of
mupirocin and oral co-trimoxazole plus topical fusidic acid in eradica-
tion of nasal carriage of methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother 1995; 39: 175–9.
80. Critchley IA, Ochsner UA. Recent advances in the preclinical
evaluation of the topical antibacterial agent REP8839. Curr Opin Chem
Biol 2008; 12: 409–17.
81. Wang L, Khosrovia B, Najafia R. N-Chloro-2,2-dimethyltaurines:
a new class of remarkably stable N-chlorotaurines Tetrahedron Letters
2008; 49: 2193–5.
82. NovaBay. http://www.novabaypharma.com/company/profile.html
(26 April 2009, date last accessed).
83. Maisch T, Bosl C, Szeimies RM et al. Photodynamic effects of
novel XF porphyrin derivatives on prokaryotic and eukaryotic cells.
Antimicrob Agents Chemother 2005; 49: 1542–52.
84. Destiny Pharma. http://www.destinypharma.com/index.shtml
(26 April 2009, date last accessed).
85. Phico Therapeutics. http://www.phicotherapeutics.co.uk (26 April
2009, date last accessed).
86. Helperby Therapeutics. http://helperbytherapeutics.com (26 April
2009, date last accessed).
87. NICE. http://www.nice.org.uk/nicemedia/pdf/CG74FullGuideline.
pdf (26 April 2009, date last accessed).
Review
15
